If you or a loved one is taking Tysabri and experiencing new neurological symptoms such as confusion, weakness on one side of the body, or vision changes, it is important to understand the potential link to progressive multifocal leukoencephalopathy (PML). The recognition of PML in the context of disease-modifying therapies has evolved through decades of clinical observation and pharmacovigilance. This page covers the early signs, risk factors, and monitoring strategies for Tysabri-associated PML.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, highlighting this risk and mandating that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML, with immediate withholding of dosing at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a demyelinating disease that affects the brain's white matter, leading to progressive neurological deficits. Clinical presentation can vary but often includes cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is based on clinical, radiological, and laboratory findings, including detection of JCV DNA in cerebrospinal fluid or brain biopsy (https://pubmed.ncbi.nlm.nih.gov/40922664/). In a large retrospective cohort study of 456 PML cases observed between 1987 and 2024, the disease was confirmed as definite in 82.4% of cases and as clinico-radiological in 17.6% (https://pubmed.ncbi.nlm.nih.gov/40922664/). This study underscores the severity and diagnostic challenges of PML, particularly in immunocompromised populations.
The pharmacological mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 beta-1 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. While this reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance against JCV, allowing the virus to reactivate and cause PML. The FDA label identifies three key risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML, and the risk increases with cumulative exposure to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical trial data further illustrate the risk. In trials involving 1869 patients with multiple sclerosis treated for a median of 120 weeks, two cases of PML were observed, both in patients who had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). A third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight that PML can occur even with relatively short exposure, though longer treatment duration is a significant risk factor.
The adequacy of warnings regarding Tysabri and PML is a critical consideration for affected patients. The FDA boxed warning clearly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also emphasizes the need for monitoring and immediate withholding of dosing at the first sign or symptom suggestive of PML. Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are informed of the risks and that appropriate monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients may develop PML, raising questions about whether the warnings were sufficient to prevent harm. For patients who develop PML after Tysabri exposure, attorney-related considerations may arise. The timeline between exposure and documented harm is variable. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can also occur earlier, especially in patients with additional risk factors such as prior immunosuppressant use. The retrospective cohort study of 456 PML cases provides broader context, showing that PML can occur across various underlying conditions and timeframes (https://pubmed.ncbi.nlm.nih.gov/40922664/). This variability underscores the importance of careful risk assessment and monitoring. Patients affected by Tysabri-associated PML may seek legal counsel to explore options regarding the adequacy of warnings and potential liability. The FDA label includes a boxed warning, but some patients may argue that the risks were not adequately communicated or that monitoring protocols were insufficient. The TOUCH Prescribing Program is designed to mitigate risk, but its effectiveness in preventing all cases of PML is limited. Attorney considerations may involve reviewing medical records to determine whether the patient's risk factors were properly assessed and whether signs of PML were promptly recognized.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. Tysabri works by blocking immune cells from entering the brain, which can allow the JC virus to reactivate and cause PML. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML symptoms include cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is based on clinical, radiological, and laboratory findings, including detection of JCV DNA in cerebrospinal fluid or brain biopsy (https://pubmed.ncbi.nlm.nih.gov/40922664/).
Yes, patients who develop PML after Tysabri exposure may seek legal counsel to explore options regarding the adequacy of warnings and potential liability. An attorney can review medical records to determine whether risk factors were properly assessed and whether signs of PML were promptly recognized.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.